Serum HER2 Extracellular Domain as a Potential Alternative for Tissue HER2 Status in Metastatic Gastric Cancer Patients

References

• Bang YJ . Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.J. Clin. Gastroenterol.46 (8), 637 – 648 (2012).
   PubMed Web of Science ®Google Scholar
• Ruschoff J , HannaW, BilousMet al. HER2 testing in gastric cancer: a practical approach. Modern Pathol. 25 (5), 637 – 650 (2012).
   PubMed Web of Science ®Google Scholar
• Bang YJ , Van CutsemE, FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 376 (9742), 687 – 697 (2010).
   PubMed Web of Science ®Google Scholar
• De Vita F , GiulianiF, SilvestrisNet al. Current status of targeted therapies in advanced gastric cancer. Expert Opin. Ther. Targets 16 (Suppl. 2), S29 – S34 (2012).
   PubMedGoogle Scholar
• Grabsch H , SivakumarS, GrayS, GabbertHE, MullerW. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series.Cellular Oncol.32 (1–2), 57 – 65 (2010).
   PubMed Web of Science ®Google Scholar
• Warneke VS , BehrensHM, BogerCet al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann. Oncol. 24 (3), 725 – 733 (2013).
   PubMed Web of Science ®Google Scholar
• Fusco N , RoccoEG, Del ConteCet al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Modern Pathol. 26 (6), 816 – 824 (2013).
   PubMed Web of Science ®Google Scholar
• Ross JS . Update on HER2 testing for breast and upper gastrointestinal tract cancers.Biomark. Med.5 (3), 307 – 318 (2011).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B , SmithBR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.Lancet Oncol.12 (3), 286 – 295 (2011).
   PubMed Web of Science ®Google Scholar
• Liu PC , LiuX, LiYet al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 5 (6), 657 – 664 (2006).
   PubMed Web of Science ®Google Scholar
• Codony-Servat J , AlbanellJ, Lopez-TalaveraJC, ArribasJ, BaselgaJ. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.Cancer Res.59 (6), 1196 – 1201 (1999).
   PubMed Web of Science ®Google Scholar
• Xia W , ChenJS, ZhouXet al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clinical Cancer Res. 10 (11), 3815 – 3824 (2004).
   PubMed Web of Science ®Google Scholar
• Lam L , McAndrewN, YeeM, FuT, TchouJC, ZhangH. Challenges in the clinical utility of the serum test for HER2 ECD.Biochim. Biophys. Acta1826 (1), 199 – 208 (2012).
   PubMed Web of Science ®Google Scholar
• Kono K , NaganumaH, SekikawaTet al. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. Tumour Biol. 21 (3), 139 – 144 (2000).
   PubMedGoogle Scholar
• Takehana T , KunitomoK, KonoKet al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 98 (6), 833 – 837 (2002).
   PubMed Web of Science ®Google Scholar
• Tsigris C , KarayiannakisAJ, SyrigosKNet al. Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res. 22 (5), 3061 – 3065 (2002).
   PubMed Web of Science ®Google Scholar
• Narita T , SeshimoA, SuzukiM, MurataJ, KameokaS. Status of tissue expression and serum levels of HER2 in gastric cancer patients in Japan.Hepatogastroenterology60 (125), 1083 – 1088 (2013).
   PubMedGoogle Scholar
• Carlson RW , MoenchSJ, HammondMEet al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J. Natl Compr. Canc. Netw. 4 (Suppl. 3), S1 – S22 ; quiz S23–S24 (2006).
   PubMedGoogle Scholar
• Hayashi N , NakamuraS, TokudaYet al. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int. J. Clin. Oncol. 17 (1), 55 – 62 (2012).
   PubMed Web of Science ®Google Scholar
• Witzel I , LoiblS, Von MinckwitzGet al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res. Treat. 123 (2), 437 – 445 (2010).
   PubMed Web of Science ®Google Scholar
• Sorensen PD , JakobsenEH, LangkjerSTet al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin. Chem. Lab. Med. 47 (9), 1117 – 1123 (2009).
   PubMed Web of Science ®Google Scholar
• Krainer M , BrodowiczT, ZeillingerRet al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54 (6), 475 – 481 (1997).
   PubMed Web of Science ®Google Scholar
• Ardavanis A , KountourakisP, KyriakouFet al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 13 (4), 361 – 369 (2008).
   PubMed Web of Science ®Google Scholar
• Mimura K , KonoK, HanawaMet al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clinical Cancer Res. 11 (13), 4898 – 4904 (2005).
   PubMed Web of Science ®Google Scholar
• Pietras RJ , PegramMD, FinnRS, ManevalDA, SlamonDJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.Oncogene17 (17), 2235 – 2249 (1998).
   PubMed Web of Science ®Google Scholar
• Pietras RJ , PoenJC, GallardoD, WongvipatPN, LeeHJ, SlamonDJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.Cancer Res.59 (6), 1347 – 1355 (1999).
   PubMed Web of Science ®Google Scholar
• Lipton A , LeitzelK, AliSMet al. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer 117 (21), 5013 – 5020 (2011).
   PubMed Web of Science ®Google Scholar
• Witzel I , LoiblS, Von MinckwitzGet al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial. Br. J. Cancer 107 (6), 956 – 960 (2012).
   PubMed Web of Science ®Google Scholar